Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer

The beneficial effects of cyclo-oxygenase (COX) inhibitors in both colon cancer and adenomatous polyps suggest a role for the prostanoid pathway in epithelial malignancy. Although variable prostanoid synthesis in non-small cell lung cancer (NSCLC) has been demonstrated in freshly obtained tissue, COX messenger ribonucleic acid (mRNA) and protein localization in such tumours had not been investigated ex vivo. Thirty-four cases of primary NSCLC were examined for both constitutive (COX-1) and inducible COX (COX-2) by means of in situ hybridization and immunohistochemistry. COX-1 mRNA expression was absent or below the level of detection via in situ hybridization. COX-1 immunohistochemistry demonstrated uniform faint cytoplasmic staining in tumour cells and stromal inflammatory cells. Semiquantitative analysis of COX-2 expression in NSCLC demonstrated the highest levels of both mRNA and protein in adenocarcinoma cells (n=10, p<0.005 compared with large cell and squamous cell carcinoma), intermediate and variable expression in large cell carcinoma (n=11) and low or absent expression in squamous cell tumours (n=13). Levels of COX-2 expression in infiltrating inflammatory cells was the same in all tumour types. In conclusion, tumour cell cyclo-oxygenase-2 rather than cyclo-oxygenase-1 expression may account for the variable prostanoid production seen in non-small cell lung cancer, and primary lung adenocarcinoma expresses the highest levels of cyclooxygenase-2. Assessment of cyclo-oxygenase-2 expression ex vivo should be performed in studies examining the potential therapeutic effects of cyclo-oxygenase inhibitors in non-small cell lung cancer.

This article has been cited by other articles:

				T. Naruse, Y. Nishida, K. Hosono, and N. Ishiguro Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes Carcinogenesis, March 1, 2006; 27(3): 584 - 592. [Abstract] [Full Text] [PDF]

				L. Ermert, C. Dierkes, and M. Ermert Immunohistochemical Expression of Cyclooxygenase Isoenzymes and Downstream Enzymes in Human Lung Tumors Clin. Cancer Res., May 1, 2003; 9(5): 1604 - 1610. [Abstract] [Full Text] [PDF]

				M. Dohadwala, R. K. Batra, J. Luo, Y. Lin, K. Krysan, M. Pold, S. Sharma, and S. M. Dubinett Autocrine/Paracrine Prostaglandin E2 Production by Non-small Cell Lung Cancer Cells Regulates Matrix Metalloproteinase-2 and CD44 in Cyclooxygenase-2-dependent Invasion J. Biol. Chem., December 20, 2002; 277(52): 50828 - 50833. [Abstract] [Full Text] [PDF]

				G E Goodman Lung cancer * 1: Prevention of lung cancer Thorax, November 1, 2002; 57(11): 994 - 999. [Abstract] [Full Text] [PDF]

				S. A. Wardlaw, N. Zhang, and S. A. Belinsky Transcriptional Regulation of Basal Cyclooxygenase-2 Expression in Murine Lung Tumor-Derived Cell Lines by CCAAT/Enhancer-Binding Protein and Activating Transcription Factor/cAMP Response Element-Binding Protein Mol. Pharmacol., August 1, 2002; 62(2): 326 - 333. [Abstract] [Full Text] [PDF]

				J. M. Wallace Nutritional and Botanical Modulation of the Inflammatory Cascade--Eicosanoids, Cyclooxygenases, and Lipoxygenases-- As an Adjunct in Cancer Therapy Integr Cancer Ther, March 1, 2002; 1(1): 7 - 37. [Abstract] [PDF]

				F. A. Wollheim Selective Cox-2 inhibition in man--therapeutic breakthrough or cosmetic advance? Rheumatology, September 1, 2000; 39(9): 935 - 938. [Full Text] [PDF]

				M. Dohadwala, J. Luo, L. Zhu, Y. Lin, G. J. Dougherty, S. Sharma, M. Huang, M. Pold, R. K. Batra, and S. M. Dubinett Non-small Cell Lung Cancer Cyclooxygenase-2-dependent Invasion Is Mediated by CD44 J. Biol. Chem., June 8, 2001; 276(24): 20809 - 20812. [Abstract] [Full Text] [PDF]